Bionovo, Inc. announced today that the U.S. National Institutes of Health (NIH), National Center for Complementary and Alternative Medicine (NCCAM) Small Business Technology Transfer Program, has approved and funded a grant to be shared by Bionovo and Dr. Dale Leitman from the University of California at Berkeley (UCB). The grant will fund the first phase in a planned multi-phase study to evaluate Bionovo's plant derived tissue selective estrogen receptor modulators for preventing obesity and the metabolic syndrome.
Menopause is associated with about a 10-15 pound weight gain and a redistribution of fat to the abdomen. The increase in abdominal fat, also known as visceral fat, is known to cause inflammation which can lead to metabolic syndrome. Metabolic syndrome represents a major public health burden because it increases the risk of cardiovascular disease and Type 2 diabetes. In the US, an estimated 25% of the population (50 million people) is classified as having this condition, which has led to enormous health care expenditures.
"Our laboratory has been collaborating with Bionovo to understand the mechanism of Bionovo's very promising novel selective estrogen receptor modulators to prevent diseases that occur during menopause.
This award from NIH is a testament to the potential of Bionovo's compounds to transform hormone therapy for menopausal women and the importance of understanding the biological basis for their unique actions," said Dr. Dale Leitman, M.D., Ph.D. from the Department of Nutrition and Toxicology, University of California, Berkeley. "To date, our results have demonstrated that Bionovo's drugs behave very selectively in that they reduce body mass and fat re-distribution without causing breast or uterine cell proliferation in mice. The funds from NIH will be used to further evaluate their safety in a variety of animal models." "Gender differences in health and disease are widely known, yet they have not been sufficiently explored by the biopharmaceutical industry.
The potential market for drugs for the treatment of female obesity is enormous. This grant will allow Bionovo, a leader in women's health, to continue its groundbreaking research on developing safer, efficacious drugs for the treatment of major health indications that are currently poorly served," said Isaac Cohen, O.M.D., Bionovo's Chairman and CEO. "The treatment of obesity and the prevention of metabolic syndrome are crucial for maintaining the health of women."